-+ 0.00%
-+ 0.00%
-+ 0.00%

Biovica International Wins Testing Services Deal for Early Breast Cancer Treatment Trial

MT Newswires·08/19/2026 05:04:01
Listen to the news
05:04 AM EDT, 08/19/2026 (MT Newswires) -- Biovica International (BIOVIC-B.ST) secured a contract worth $287,000 to deliver its DiviTum TKa testing assay services to an existing undisclosed client. The customer will use the Swedish biotechnology group's pharma services for its early-stage clinical development breast cancer treatment trial that will evaluate a CDK2/4 inhibitor field. The company noted that it will start sample testing between January 2027 and February 2027 at its CLIA-certified laboratory in California, US.